Core Viewpoint - The Hong Kong Stock Connect innovative drug ETF managed by E Fund (159316) has shown a strong rebound, rising over 4.5% in early trading, indicating positive market sentiment towards innovative drug development in China [1] Group 1: Innovative Drug Development - Innovent Biologics' anti-CTLA-4 monoclonal antibody "Daboshu" has been approved as the first domestic drug of its kind, filling a gap in the market [1] - The TROP2 ADC "Dercumab" jointly developed by AstraZeneca and Daiichi Sankyo has been approved for breast cancer indications in China, strengthening the ADC sector [1] Group 2: Business Development (BD) Growth - By December 31, 2025, the total transaction amount for China's innovative drug BD overseas licensing is expected to reach $135.655 billion, with upfront payments of $7 billion and a total of 157 transactions, marking historical highs across various metrics [1] - Recent BD transactions include: - Tongyi Medicine's peptide-conjugated drug CBP-1018 for prostate cancer licensed to MultiValent Biotherapies for $2 billion [1] - Ascletis Pharma's ADC drug SIM0613 licensed to Ipsen for $1.06 billion [1] - GRAIL's pan-KRAS inhibitor entering a Co-Co collaboration with AstraZeneca for over $2 billion, setting a record for clinical-stage small molecule collaborations [1] Group 3: Key Products - E Fund's Hong Kong Stock Connect innovative drug ETF (159316, linked A/C: 024328/024329) [1] - E Fund's Hong Kong Stock Connect pharmaceutical ETF (513200, linked A/C: 018557/018558) [1] - E Fund's Hang Seng Biotechnology ETF (159105) [1]

Core Viewpoint - The stock price of Jacob Pharma continues to decline despite a significant licensing agreement with AstraZeneca, raising concerns in the industry about the low upfront payment relative to the total deal value [2][22]. Group 1: Licensing Agreement Details - Jacob Pharma announced a global exclusive licensing agreement with AstraZeneca for its KRAS inhibitor, with an upfront payment of $100 million and a total deal value of up to $1.915 billion, including tiered royalties on net sales outside of China [2][22]. - The agreement is considered the largest collaboration for a small molecule anti-cancer drug in clinical stages in China, yet the stock fell by 13.58% on the first trading day after the announcement [2][22]. Group 2: Market Reaction and Company Strategy - The market's reaction to licensing deals has been generally cold this year, with other biotech companies like Rongchang Biotech and Innovent Biologics also experiencing stock declines post-announcement [6][26]. - Jacob Pharma's business model is heavily reliant on licensing out, which was established from its inception, and the company aims to focus on "First in class" products, avoiding "Best in class" options [6][27]. Group 3: Financial Position and Future Outlook - As of June 30, 2025, Jacob Pharma reported cash and cash equivalents of approximately RMB 1.07 billion, indicating a relatively strong cash position despite the challenging capital environment [8][28]. - The company plans to have ten products in clinical trials that rank among the top three globally by 2024, which could lead to more licensing opportunities [38][39]. Group 4: Leadership and Vision - CEO Wang Yinxiang emphasizes the importance of maintaining a balance between research and market presence, advocating for a robust production and sales system to avoid being solely reliant on external financing [39][40]. - Wang's background includes founding Jacob Pharma after a successful tenure at Betta Pharmaceuticals, where he recognized the potential for innovation in the Chinese pharmaceutical market [30][31].

Core Viewpoint - The article discusses the strategic moves of 加科思 (Gakosi) in the biopharmaceutical sector, particularly focusing on its divestment of a cardiovascular project to 海松资本 (Haisong Capital) and the subsequent reinvestment into its core oncology pipeline, especially the development of a Pan-KRAS inhibitor [2][4][9]. Group 1: Transaction Details - 加科思 announced a capital increase and equity transfer involving a cardiovascular treatment project, previously held by its subsidiary 加科瑞康 (Gakosi Ruikang), to 海松资本, which will acquire 80% of the subsidiary [2][4]. - The transaction includes an initial payment of 125 million yuan and a milestone payment of 75 million yuan, totaling 200 million yuan, which will be used for the development, production, and commercialization of its core oncology pipeline [2][3][4]. Group 2: Strategic Focus - Following the divestment of non-core assets, 加科思 aims to concentrate on the oncology field, enhancing its cash flow and retaining a 10% stake in 加科瑞康 for potential future benefits [4][6]. - The company has a strong focus on the Pan-KRAS inhibitor, which is a significant target in its pipeline, as KRAS mutations are linked to a high percentage of cancer cases [11][13]. Group 3: Clinical Development Plans - 海松资本 plans to leverage China's clinical advantages to expedite the development of the pipeline, with intentions to submit an IND application in the first half of next year, aiming to enter clinical trials [7][9]. - The Pan-KRAS inhibitor is currently undergoing I/IIa phase clinical trials in China and the U.S., with results expected to be announced in mid-2026 [14][15]. Group 4: Market Context - The article highlights the competitive landscape for Pan-KRAS inhibitors, noting that other companies like Pfizer and BeiGene are also advancing similar projects in clinical stages [15]. - 加科思's leadership emphasizes the potential of iADC (immune-stimulating antibody-drug conjugates) as a high-risk but high-reward area, indicating a broader strategy in innovative cancer therapies [15].

Core Viewpoint - The announcement by Gakos-B (01167.HK) regarding a capital increase and equity transfer transaction highlights a strategic shift towards focusing on its core oncology business while divesting non-core assets, specifically a cardiovascular treatment project [2][3]. Group 1: Transaction Details - Gakos-B has entered into a transaction where Haisheng Capital will acquire 80% of the equity in Gakos-Rikang, a wholly-owned subsidiary of Gakos-B, for a total consideration of 200 million yuan, which will be used to support the development, production, and commercialization of its core oncology pipeline [2][4]. - The payment structure includes an initial payment of 125 million yuan and a milestone payment of 75 million yuan [2]. Group 2: Strategic Focus - Following the divestment, Gakos-B aims to concentrate its resources on the oncology sector, which is deemed more suitable for the company's current development stage [3][4]. - The company retains a 10% stake in Gakos-Rikang, allowing it to benefit from potential future gains [2]. Group 3: Investment and Development Plans - Haisheng Capital, a diversified investment firm with over 25 billion yuan under management, sees significant potential in the Chinese innovative drug sector and plans to leverage clinical advantages in China to expedite the development of the cardiovascular pipeline [4][5]. - Gakos-B's 200 million yuan from the equity transfer is expected to cover a substantial portion of its research and development expenses for the next six months, with a focus on the Pan-KRAS inhibitor and other innovative oncology projects [5][9]. Group 4: Research and Development Focus - The Pan-KRAS inhibitor is a priority for Gakos-B, which aims to develop a leading global product in this area, as KRAS mutations are linked to a significant percentage of cancer cases [6][8]. - Gakos-B is currently conducting I/IIa phase clinical trials for its Pan-KRAS inhibitor in both China and the United States, with results expected in mid-2026 [9].